• All Topics
  • Health Technology Assessment (HTA)
  • Antimicrobial Resistance (AMR)
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real-World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme
  • IRA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Health Technology Assessment…
  • Israel

NICE enough? Do NICE’s Decision Outcomes Impact International HTA Decision-making?

andrew-butler-aUu8tZFNgfM-unsplash
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Gene therapies

Are Recommendations for HTA of Gene Therapies Being Achieved?

cover 3
Read more
  • Chronic Diseases
  • Value, Affordability, and…
  • Dermatology

The Burden of Hidradenitis Suppurativa on Patients, the NHS and Society

jakob-braun-HfOOKAPsE28-unsplash
Read more
  • Digital Health
  • Economics of Innovation
  • Mental Health

Dementia in the UK: Estimating the Potential Future Impact and Return on Research Investment

image option 1
Read more
  • Precision Medicine
  • Economics of Innovation

The Case for Expanding Uptake of Next-Generation Sequencing for Lung Cancer in Europe

NGS report_AdobeStock_406823942_portrait
Read more
  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

A Novel Incentive Model for Uptake of Diagnostics to Combat Antimicrobial Resistance

Roche AMR diangostics_national-cancer-institute-2fyeLhUeYpg-unsplash_portrait
Read more
  • Health Technology Assessment…
  • Value, Affordability, and…
  • Pricing and Reimbursement

Real-World Evidence: Current Best Practice for Reimbursement Decision-Making

RWE_clay-banks-b5S4FrJb7yQ-unsplash_portrait
Read more
  • Value-Based Pricing
  • Economics of Innovation
  • Pricing and Reimbursement

Delivering the Triple Win: A Value-Based Approach to Pricing

Triple_Win_AdobeStock_249059909_portrait_v2
Read more
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real-World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • IRA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 28th December 2016

New OHE Research Paper: Extrapolation from Progression Free Survival to Overall Survival in Oncology

The Office of Health Economics, in a research project funded by the Pharmaceutical Oncology Initiative (POI), has published a report entitled: Extrapolation from Progression Free Survival to Overall Survival in Oncology. The Office of Health Economics, in a research project…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

The Office of Health Economics, in a research project funded by the Pharmaceutical Oncology Initiative (POI), has published a report entitled: Extrapolation from Progression Free Survival to Overall Survival in Oncology.

The Office of Health Economics, in a research project funded by the Pharmaceutical Oncology Initiative (POI), has published a new report entitled: Extrapolation from Progression Free Survival to Overall Survival in Oncology. 

A clinical endpoint is an aspect of a patient’s clinical or health status that is measured to assess the benefit or harm of a treatment. It aims to measure the impact on how a patient feels, functions and survives.

The increase in the length of overall survival (OS) is the ‘gold standard’ endpoint for clinical trials assessing the efficacy of cancer treatments. However, measuring OS often requires a large number of patients and long follow-ups. This may involve considerable cost and perhaps more importantly, delay patients’ access to new cancer drugs.

If an endpoint that is highly correlated with OS can be measured much earlier, it can be used as a surrogate for OS. The most common surrogate used in oncology is progression-free survival (PFS), which for some cancer types and especially for later-line therapies, has a high correlation with OS. On the other hand, if PFS and OS are not strongly correlated, the use of PFS as a surrogate for OS may lead to treatments with large survival gains being rejected or treatments with small or even negative survival gains being accepted.

Regulatory decision-makers, such as EMA and FDA, have used PFS as the basis for marketing approval of some new therapies. However, there are concerns in the scientific community regarding the validity of PFS as a surrogate for OS. Factors such as crossover from control to experimental arms in clinical trials as well as the effect of subsequent therapies may distort the relationship between PFS and OS. In addition, some new therapies may slow tumour growth considerably, but with little or no initial tumour shrinkage. Even though PFS and OS may not be highly correlated in such circumstances, such a therapy may be many patients’ best option. 

The report contains a literature review analysing the use of extrapolating PFS to OS in oncology as well as determining key limitations, weaknesses and gaps in the current literature and methods used to test PFS surrogacy. The review shows that the validity of surrogates is affected by multiple factors such as cancer type, drug mechanism of action, phase of development, year of the trial, subsequent treatments and stage of the disease.

The second section of the report reflects the experience and opinions of relevant experts (policy makers, academics, and industry representatives) collected during a workshop and a series of interviews. There was a suggestion that NICE does not always use a surrogate outcome in its analysis if it believes that direct extrapolation of OS gives sufficient accuracy to allow for good adoption decisions to be made.

Finally, the authors review methodological advances in the statistical theory of surrogacy, and current thinking of surrogacy as an economic question rather than a clinical effectiveness question. Economic analysis could also place surrogate endpoints into a value-of-information framework. The key question is: how much information should be collected before a decision is made on the adoption (or otherwise) of a treatment? 

Access the full report here.

For more information contact Karla Hernandez-Villafuerte at OHE.

  • Measuring and Valuing Outcomes

Related News

NGS report_AdobeStock_406823942_landscape
  • News
  • July 2023

NGS testing for lung cancer across Europe still limited, despite clear case for adoption

Read more
IRA-course-graphic-for-website-news-FINAL-1
  • News
  • May 2023

New free educational program launched – Explaining the U.S. Inflation Reduction Act

Read more
Group 11119
  • News
  • February 2023

Applications open for MSc Fellowship Programme 2023

Read more
Prize event
  • News
  • January 2023

Professor Aidan Hollis wins first £40,000 OHE Policy Innovation Prize

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for OHE Insights, Events & News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in .

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!